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High diagnostic value of second 
generation CSF RT-QuIC across the 
wide spectrum of CJD prions
Alessia Franceschini1, Simone Baiardi1, Andrew G. Hughson2, Neil McKenzie3, Fabio Moda4, 
Marcello Rossi5, Sabina Capellari1,5, Alison Green3, Giorgio Giaccone4, Byron Caughey2 &  
Piero Parchi  1,5
An early and accurate in vivo diagnosis of rapidly progressive dementia remains challenging, despite 
its critical importance for the outcome of treatable forms, and the formulation of prognosis. Real-
Time Quaking-Induced Conversion (RT-QuIC) is an in vitro assay that, for the first time, specifically 
discriminates patients with prion disease. Here, using cerebrospinal fluid (CSF) samples from 239 
patients with definite or probable prion disease and 100 patients with a definite alternative diagnosis, 
we compared the performance of the first (PQ-CSF) and second generation (IQ-CSF) RT-QuIC assays, 
and investigated the diagnostic value of IQ-CSF across the broad spectrum of human prions. Our results 
confirm the high sensitivity of IQ-CSF for detecting human prions with a sub-optimal sensitivity for 
the sporadic CJD subtypes MM2C and MM2T, and a low sensitivity limited to variant CJD, Gerstmann-
Sträussler-Scheinker syndrome and fatal familial insomnia. While we found no difference in specificity 
between PQ-CSF and IQ-CSF, the latter showed a significant improvement in sensitivity, allowing 
prion detection in about 80% of PQ-CSF negative CJD samples. Our results strongly support the 
implementation of IQ-CSF in clinical practice. By rapidly confirming or excluding CJD with high accuracy 
the assay is expected to improve the outcome for patients and their enrollment in therapeutic trials.
Human transmissible spongiform encephalopathies (TSEs) or prion diseases are neurodegenerative disorders 
characterized by the conversion of a constitutively expressed cellular glycoprotein, the prion protein (PrPC), into 
an abnormally folded, beta-sheet enriched, isoform (PrPSc)1. While the mechanism of initial PrPSc formation 
remains largely unexplained, compelling evidence indicates that disease propagation involves the templated mis-
folding of PrPC by PrPSc2, 3.
Human prion diseases are highly heterogeneous disorders including four major disease groups, namely 
Creutzfeldt-Jakob disease (CJD), fatal insomnia, Gerstmann-Sträussler-Scheinker (GSS) syndrome, and var-
iably protease-sensitive prionopathy (VPSPr)4–7. Disease subtypes with distinctive molecular and pheno-
typic features can also be found within these four groups, as it is exemplified by the current recognition of six 
clinico-pathological subtypes of sporadic CJD (sCJD) correlating at molecular level with the genotype at the 
polymorphic codon 129 (methionine, M or valine, V) in the gene encoding the prion protein (PRNP) and the type 
(1 or 2) of PrPSc accumulating in the brain8, 9. This phenotypic diversity mostly relates to the biology of prions, 
which exist in different strains, thought to be enciphered in distinct PrPSc conformations, that are able to transmit 
distinctive phenotypic traits, including incubation time, clinical signs, progression rate, type and patterns of PrPSc 
deposition, and neuropathological lesions10, 11. Specifically, current evidence indicate that five out of six sCJD sub-
types (MM1, MM2C, MM2T, VV1 and VV2) behave as distinct prion strains after serial transmission into animal 
models. As the only exception, the VV2 and MV2K variants showed the same transmission properties, indicating 
a host-genotype (codon 129) effect12–15.
Due to of the significant phenotypic overlap with a number of other medical conditions which present with 
a rapidly progressive neurological syndrome, the clinical diagnosis of prion disease is often challenging. The 
introduction of diagnostic investigations such as brain diffusion weighted-MRI (DW-MRI) and surrogate CSF 
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biomarkers such as the 14-3-3 and t-tau proteins has significantly increased the clinical diagnostic confidence16, 17. 
However, because of the lack of full specificity of these investigations, the post-mortem demonstration of PrPSc in 
the CNS tissue is still required for the definitive diagnosis of prion disease18.
Recently, the Real-Time Quaking-Induced Conversion (RT-QuIC) assay has been proposed as the first specific 
in vivo diagnostic test for sCJD19. By exploiting the self-replicating (seeding) power of pathogenic PrPSc, RT-QuIC 
ultra-sensitively detects limited amounts of abnormal protein in CSF and other tissue samples20. The RT-QuIC 
technology builds on aspects of earlier QuIC21, 22 and amyloid seeding assays23, to provide high PrPSc sensitiv-
ity and specificity in a high throughput multiwell plate format with fluorescence detection. Results obtained in 
several laboratories with the first generation of this assay (PQ-CSF), mainly using full-length (23–231) hamster 
recombinant prion protein (rPrPsen) as the substrate, demonstrated a very high specificity but a suboptimal sensi-
tivity, especially in sCJD subtypes associated with PrPSc type 224–27. However, Orrù et al.28 recently introduced an 
improved, second generation RT-QuIC for CSF (IQ-CSF) assay which uses a truncated form of hamster recom-
binant PrP (rPrPsen, amino acids 90–231) as a substrate and other experimental conditions. Initial evaluation of 
the IQ-CSF assay indicated greater analytical and diagnostic sensitivity, and markedly shorter testing times29–31.
In this study, we contribute our experience with the second generation IQ-CSF in a large patient cohort includ-
ing the largest patient population analysed to date affected by atypical and rare disease subtypes. Furthermore, to 
explore the performance of IQ-CSF in full, we provide a direct comparison between PQ- and IQ- methodologies, 
focusing on a largest group of definite CJD CSF samples analysed to date that were previously tested negative by 
PQ-CSF.
Results
We investigated a total of 339 patients, including 239 CSFs from subjects with a definite (166) or probable (73) 
diagnosis of prion disease and 100 from patients with a definite alternative diagnosis (non-CJD). Specific aims 
of the study included: (i) the direct comparison of the overall performance of IQ-CSF with respect to the first 
generation RT-QuIC (PQ-CSF); (ii) the evaluation of the diagnostic accuracy of IQ-CSF across the spectrum of 
human prion disease subtypes; and (iii) the determination of the diagnostic performance of IQ-CSF in the clinical 
setting. Demographic data and investigative findings of the whole tested cohort are summarized in Table 1.
Comparison of IQ-CSF and PQ-CSF performance. To this aim we used 163 cases with a probable or 
definitive diagnosis of prion disease and 100 non-CJD cases. Samples were largely selected based on previous 
results by PQ-CSF. Most significantly, they included all prion CSF samples available to us (n = 93) that were either 
negative or only partially positive (2 out of 4 positive wells) by PQ-CSF (Suppl. Table 1).
Using IQ-CSF, 47 of the 58 cases that were negative by PQ-CSF showed a positive seeding activity (Suppl. 
Table 1). Among the 11 that remained negative under IQ-CSF conditions, 4 showed a significant blood contam-
ination; the other 7 included 1 FFI, 1 GSS P102L, 1 sCJD MM1, 1 sCJD MV2K, 2 sCJD MM2C and 1 probable 
sCJD (MV).
Classification n
Demographic data CSF Brain MRI* EEG
Gender (n 
of F) [%]
Mean age at 
onset (years)
Mean disease 
duration (months)
14-3-3 protein 
Positive/Tested [%]
t-tau > 1250 pg/mg 
Positive/Tested [%]
Positive/
Tested [%]
PSWCs/
Tested [%]
Definite sCJD 116 63 [54.3] 65.9 ± 10.5 10.1 ± 11.6 89/112 [79.5] 92/107 [85.9] 74/89 [83.1] 39/107 [36.4]
 MM1 43 67.5 ± 7.9 3.3 ± 2.2 41/43 [95.3] 40/42 [95.2] 29/35 [82.8] 29/40 [72.5]
 VV2 33 58.2 ± 8.7 6.9 ± 2.4 31/31 [100.0] 29/29 [100.0] 21/24 [87.5] 4/30 [13.3]
 MV2K 26 65.6 ± 10.2 20.3 ± 16.1 14/25 [56.0] 19/24 [79.2] 15/17 [88.2] 3/23 [13.0]
 MM2C 9 60.1 ± 15.8 21.5 ± 14.4 2/8 [25.0] 2/7 [28.6] 7/8 [87.5] 3/9 [33.3]
 MM2T 4 42.0 ± 14.5 27.0 ± 7.9 0/4 [0.0] 1/4 [25.0] 1/4 [25.0] 0/4 [0.0]
 VV1 1 64.0 13.5 1/1 [100.0] 1/1 [100.0] 1/1 [100.0] 0/1 [0.0]
Probable sCJD 73 39 [53.4] 68.1 ± 8.0 8.9 ± 7.4 62/73 [84.9] 69/73 [94.5] 56/65 [86.1] 27/65 [41.5]
 MM 39 67.2 ± 8.9 5.1 ± 5.2 37/39 [94.9] 38/39 [97.4] 31/36 [86.1] 23/35 [65.7]
 MV 24 68.3 ± 7.4 14.2 ± 7.8 15/24 [62.5] 21/24 [87.5] 17/19 [89.5] 4/21 [19.0]
 VV 10 71.1 ± 5.3 7.5 ± 4.2 10/10 [100.0] 10/10 [100.0] 8/10 [80.0] 0/9 [0.0]
Genetic CJD§ 33 22 [66.7] 60.6 ± 10.1 9.6 ± 11.5 27/33 [81.8] 31/33 [93.9] 18/23 [78.3] 9/23 [39.1]
FFI 2 50.0 ± 7.1 23, NA 0/2 [0.0] 0/1 [0.0] 0/1 [0.0] 0/1 [0.0]
GSS 6 44.0 ± 11.1 48 ± 12° 1/6 [16.7] 2/5 [40.0] 1/6 [16.7] 0/5 [0.0]
Definite vCJD 4 34.7 ± 10.4 17.5 ± 12.0 2/4 [50.0] 1/4 [25.0] 2/4 [50.0] 0/4 [0.0]
Definite iCJD 2 54.5 ± 31.8 20.0 ± 24.0 2/2 [100.0] 2/2 [100.0] 1/1 [100.0] 0/1 [0.0]
Definite VPSPr 3 71.3 ± 5.0 24.7 ± 10.1 2/3 [66.7] 1/1 [100.0] 0/3 [0.0] 0/2 [0.0]
Non-CJD 100 49 [49.0] 67.3 ± 13.2 17.9 ± 33.5 39/98 [39.8] 30/93 [32.2] 15/72 [20.8] 20/80 [25.0]
Table 1. Demographic features and results of diagnostic investigations in the tested patient cohort. *According 
to Zerr et al.18, MRI findings were considered positive when showing (either in DW or FLAIR sequences) a 
hyperintensity in the striatum or in at least two cortical regions; therefore only MRI studies including DW and/
or FLAIR sequences were taken into account. §Genetic CJD cases included the following PRNP haplotypes: 
E200K-129M, V210I-129M, D178N-129V, R208H-129V, and E219G-129V. °3 patients are still alive.
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The analysis of the 104 samples that were positive in both assays revealed a significant increase in the percent-
age of positive wells under IQ-CSF conditions (Suppl. Table 1).
Furthermore, the comparison of the fluorescence curve responses in a group of 25 sCJD patients yielding 
a positive seeding activity under both assay conditions (Fig. 1A) confirmed that IQ-CSF is associated with a 
marked reduction of the mean lag phase (Fig. 1B, IQ-CSF = 7.6 ± 0.5 hours; PQ-CSF = 46 ± 3, n = 25, p < 0.001) 
and a significantly higher fluorescence response (Fig. 1C, IQ-CSF = 78.8 ± 0.4%; PQ-CSF = 53.0 ± 3.0%; n = 25, 
p < 0.001).
To determine whether IQ-CSF can detect a difference in seeding activity between prion samples that were 
either negative or positive under PQ-CSF conditions, we also compared the IQ-CSF fluorescence curves (Suppl. 
Figure 1A) between PQ-positive/IQ-positive and PQ-negative/IQ-positive samples. Interestingly, PQ-positive/
IQ-positive samples had a lower lag phase (8.3 ± 0,3 vs 11.5 ± 0.9; n = 104, 47; p < 0.05; Suppl. Figure 1B), a 
higher ThT max (3816 ± 64 vs 3042 ± 106; n = 104, 47; p < 0.001; Suppl. Figure 1B), and a higher area under the 
curve (AUC) (124000 ± 2300 vs 102000 ± 4800; n = 104, 47; p < 0.001; Suppl. Figure 1B).
Finally, no sample from the non-CJD group (Table 2) yielded a positive response, resulting in a test specificity 
of 100%.
In summary, the present results confirm that IQ-CSF is associated with a significant increase in test speed and 
sensitivity while maintaining the very high specificity of PQ-CSF. Remarkably, IQ-CSF allowed the identification 
of 81% of those CJD samples which had previously tested negative by PQ-CSF.
Analysis of IQ-CSF sensitivity across the spectrum of human prions. To this aim we evaluated the 
IQ-CSF results in a panel of 239 samples, representative of all major human prion disease subtypes (Table 1). 
Figure 1. Comparison of kinetics and time to threshold between IQ-CSF and PQ-CSF RT-QuIC assays. (A) 
Averaged fluorescence kinetics of 25 sCJD (12 MM1, 8 VV2 and 5 MV2K) CSFs under, respectively, IQ-CSF 
(white) and PQ-CSF (black) conditions. Traces represent the mean ± SD of ThT fluorescence, the dot line the 
positivity threshold for both assays. (B) Comparison of the time to reach the threshold (lag phase) by IQ-CSF 
and PQ-CSF (n = 25 sCJD, p < 0.001). (C) Percentage of increment of ThT fluorescence with respect to the 
threshold by IQ-CSF and PQ-CSF (n = 25 sCJD, p < 0.001).
www.nature.com/scientificreports/
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The results of the IQ-CSF assay for these different diagnostic groups are summarized in Table 3 and Fig. 2. 
Remarkably, the assay detected PrPSc with a very high sensitivity across the whole spectrum of sporadic CJD 
prions, with only minor variations among disease subtypes (Table 3 and Fig. 2A). Specifically, the test showed a 
92 to 100% sensitivity for each of the three most common sCJD types (e.g. MM1, VV2, and MV2K), represent-
ing overall more than 90% of all CJD patients, and a lower, sub-optimal sensitivity only for the rare MM2C and 
MM2T sCJD subtypes. Interestingly, the IQ-CSF was also positive in all tested VPSPr cases.
The comparison of the maximum fluorescence response (ThT max) among sporadic disease subtypes revealed 
a statistically significant difference between MM1 and MM2C (3900 ± 100, n = 40 vs 2800 ± 200, n = 6, p < 0.05) 
and between MM1 and VPSPr (3900 ± 100, n = 40 vs 2500 ± 230, n = 3, p < 0.05) (Fig. 2C). Similarly, the com-
parison of lag phases showed a statistically significant difference between MM1 and MM2C (8.9 ± 0.5, n = 40 vs 
13.3 ± 3, n = 6, p < 0.05) and between MM1 and VPSPr (8.9 ± 0.5, n = 40 vs 25.0 ± 3, n = 3, p < 0.05) (Fig. 2D).
Regarding gCJD, IQ-CSF detected the prion seeding activity even in patients carrying rare PRNP hap-
lotypes associated with atypical disease phenotypes, such as R208H-129V, E219G-129V, and D178N-129V 
(Suppl. Table 2). More significantly, between the two gCJD groups with at least 10 cases (Fig. 2B), the E200K-
129M showed a higher ThT max mean value and a shorter lag phase in comparison to V210I-129M (ThT 
max = 4100 ± 130, n = 20 vs 3800 ± 300, n = 10; Lag phase = 5.2 ± 0.7, n = 20 vs 8.5 ± 0.7 n = 10, p < 0.05). 
Moreover, the lag phase was significantly shorter in E200K-129M in comparison to sCJD MM1, MV2K and VV2 
(p < 0.05).
Finally, the results we obtained in a limited number of cases affected by rare genetic and acquired prion dis-
eases such as GSS, FFI and vCJD suggest a rather low sensitivity of the assay for these variants.
In summary, we demonstrated the high sensitivity of IQ-CSF across the spectrum of human pri-
ons with a sub-optimal sensitivity for the MM2C and MM2T, and a low sensitivity limited to variant CJD, 
Gerstmann-Sträussler-Scheinker syndrome and fatal familial insomnia. Furthermore, sCJD MM2C and VPSPr 
prions appears to have a lower RT-QuIC seeding potency in comparison to the other most common sCJD sub-
types (sCJD MM1, VV2 and MV2K). Finally, similarly to PQ-CSF, the IQ assay demonstrated that gCJD E200K-
129M is the human prion disease subtype associated with the shortest lag phase.
Overall performance of IQ-CSF in a “clinically” representative CJD population. To estimate the 
diagnostic performance of IQ-CSF in a clinical setting, we analyzed the assay results in a group of 187 unselected 
cases with a definitive neuropathologic or clinical diagnosis (either CJD or non-CJD), which were submitted to 
our Lab between January 2011 and March 2017. The results obtained for these groups are summarized in suppl. 
Table 3. At the chosen RFU threshold, 141 of the 145 CJD cases had a positive assay. The calculated test sensitivity 
was 97.2%, while the test’s positive predictive value (PPV) and negative predictive value (NPV) were 100% and 
91.3% respectively.
Discussion
In this study we have applied IQ-CSF, the second generation RT-QuIC prion assay, to a patient cohort including 
the largest population analysed to date affected by the less common disease subtypes. Furthermore, we provide 
a direct comparison between the first and second generation prion RT-QuIC, taking advantage of a very large 
group of samples from definite CJD cases previously tested under PQ-CSF conditions27. The results confirm that, 
while PQ-CSF and IQ-CSF show a comparable performance in terms of specificity, IQ-CSF is associated with a 
remarkable increase in sensitivity, allowing the detection of 81% of CJD samples tested negative by PQ-CSF. Since 
in those CSF samples which tested negative by PQ-CSF, the mean seeding activity as detected by IQ-CSF was 
lower than in samples which tested positive under both conditions, the collected data clearly indicate that this 
novel assay is associated with a lower limit of detection for seeding prions. Moreover, they confirm that the added 
value of IQ-CSF goes beyond the crude numbers reflecting the increased sensitivity. Indeed, besides the faster 
response allowing a ~40-h reduction in average detection time for positive samples in comparison to PQ-CSF, 
IQ-CSF is also associated with a stronger fluorescence readings and a significant reduction of unclear or incon-
clusive results (e.g. when the well repeats repeatedly give an equivocal response).
Diagnostic categories
14-3-3 protein 
positive/tested (%)
t-tau > 1250 pg/ml 
positive/tested (%)
brain MRI positive/
tested (%)
Definite diagnosis (n)
pathological clinical*
Alzheimer’s disease 4/17 (23.5) 4/15 (26.7) 2/13 (15.4) 16 1
Lewy body dementia 1/11 (9.1) 2/11 (18.2) 0/6 (0.0) 12
Other neurodegenerative diseases° 2/6 (33.3) 3/6 (50.0) 1/6 (16.7) 4 2
Vascular dementia 6/10 (60.0) 4/9 (44.4) 2/7 (28.6) 10
CNS malignancy 5/7 (71.4) 4/7 (57.1) 2/3 (66.7) 7
Encephalitis (infectious or autoimmune) 12/28 (42.8) 9/28 (32.1) 5/23 (21.7) 10 18
Toxic/metabolic encephalopathies 4/9 (44.4) 4/10 (40.0) 1/7 (14.3) 6 4
No distinctive neuropathology (PrPSc negative) 4/10 (40.0) 0/7 (0.0) 2/7 (28.6) 10
Table 2. Diagnostic categories of non-CJD cases. *Criteria for the definitive clinical diagnosis are provided in 
the methods. °Other neurodegenerative diseases include Huntington disease (n = 1), corticobasal degeneration 
(n = 1), progressive supranuclear palsy (n = 1), frontotemporal dementia (n = 1), argyrophilic grain disease 
(n = 1), and primary age-related tauopathy (n = 1).
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A critical issue concerning the evaluation of any novel diagnostic assay for prion disease is related to the extent 
of clinical heterogeneity shown by these patients. This is a major point of difficulty in the clinical diagnosis and 
differentiation of prion diseases against other neurological disorders, not only because of the broad spectrum of 
clinical situations where the suspicion of prion disease can be raised, but also because the accuracy of diagnostic 
assays often varies significantly according to the disease subtype. This has been shown, not only for surrogate 
biomarkers such as proteins 14-3-3 and t-tau, but also for PQ-CSF27. Thus, a critical question is how well IQ-CSF 
detects and differentiates the less common and often atypical prion disease variants. Our results show that the 
high sensitivity of IQ-CSF extends to the majority of human prion strains. Most significantly, we demonstrated 
in the largest series of definite cases analyzed to date (n = 59), a 98% diagnostic sensitivity for the two subtypes 
associated with the V2 prion strain (VV2 and MV2K subtypes comprising about 30% of all sCJD cases). This is 
significant in that it will not only raise the overall accuracy of routine diagnosis but also improve the detection 
and diagnosis of these atypical subtypes. Due to the relatively frequent atypical clinical onset and/or the relatively 
slow disease progression (MV2K subtype), in such cases the clinical diagnosis of probable sCJD, when reached, is 
often delayed. In a recent study32, we found that about 20% of VV2 cases manifest symptoms and signs limited to 
the cerebellar/visual domain at time of first hospitalization and therefore do not fulfill current clinical criteria for 
possible sCJD, which are required to implement a diagnosis of probable sCJD based on surrogate CSF biomarkers 
and/or MRI findings18. Similarly, the diagnosis of probable sCJD in subjects with the MV2K subtype is reached, 
on average, only seven months after clinical onset (P.Parchi and coll., unpublished observation).
As far as the other sCJD subtypes are concerned, which are all very rare, our results show a lower sensitivity of 
the IQ-CSF for the MM2C and, possibly, MM2T. Most significantly, for MM2C our results are in line with those 
of Foutz et al.29, namely showing lower values in both assay sensitivity and seeding effect in MM2C in comparison 
to MM1. By combining our 9 cases with the 9 analyzed by Foutz et al., the overall calculated sensitivity of IQ-CSF 
for sCJD MM2C is 68%. Since M2C prions have a significantly reduced transmission efficiency relative to M1 
prions in the most compatible host genotype33, these results may indicate that the response detected by IQ-CSF 
reflects such a property of prions. Indeed, previous studies, combining brain sample dilutions and/or the use of 
different substrates have already demonstrated the potential of RT-QuIC for prion strain discrimination34, 35. 
However, whether these preliminary data reflect differences in abnormal PrP concentrations, strain-specific PrPSc 
properties or both remain to be seen. Thus, additional work with each type of human prions will be required to 
better establish the quantitative relationships between RT-QuIC seeding activity and the levels of PrPSc in tissue 
samples.
Finally, although with data obtained from a limited number of samples, we demonstrated here for the first 
time that the IQ-CSF may detect prion seeding activity even in VPSPr, a highly distinctive prion disease phe-
notype, which is notoriously associated with a low sensitivity of surrogate biomarker assays6. Furthermore, as 
Figure 2. IQ-CSF RT-QuIC assay sensitivity in sporadic, genetic and acquired prion diseases according to 
CJD subtype or PRNP mutation. The upper boxes show the ThT fluorescence traces of (A) CJD subtypes MM1 
(n = 40), VV2 (n = 33), MV2K (n = 24), MM2T (n = 3), MM2C (n = 6), VPSPr (n = 3), non-CJD (n = 100) 
and (B) CJD subtypes MM1 (n = 40), gCJD E200K-129M (n = 20), and gCJD V210I-129M (n = 10), non-CJD 
(n = 100). Data are expressed as mean ± SEM. The histograms and/or the scatter plot graphs show the lag phases 
(C) and ThT max (D) of the same disease groups.
www.nature.com/scientificreports/
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for sCJD MM2C, we detected a significantly lower seeding effect in VPSPr in comparison to the most common 
sCJD prions (e.g. M1 and V2 strains), further supporting the idea that IQ-CSF may, with the limitations outlined 
above, differentiate between prions with relatively high or low propagation efficiency (in their most compatible 
host genotype).
The present results, combined with those of other recent studies29–31, demonstrate that prion CSF RT-QuIC is 
not only fully specific, but also has even higher sensitivity than the surrogate biomarker assays making it the most 
powerful currently available tool for the clinical diagnosis of prion disease in humans. Given the high diagnostic 
performance of IQ-CSF, the role of surrogate CSF markers in the differential diagnosis of rapidly progressive 
neurological syndromes should be reconsidered. If a complementary role of such assays beside RT-QuIC should 
be envisaged, the choice should definitely go towards biomarkers such as t-tau or, perhaps, the neurofilament 
proteins36 (which are increasingly used in the differential diagnosis of neurodegenerative dementia), rather than 
14-3-3, a biomarker whose application has been limited to the differential diagnosis of CJD. Indeed, in case where 
the RT-QuIC assay is negative, the result of the t-tau assay may be helpful in re-directing the diagnostic work-up.
In conclusion, the results of the present study strongly support the rapid implementation of IQ-CSF testing in 
clinical practice. By rapidly confirming or excluding the CJD diagnoses with high accuracy the assay is expected 
to improve the outcome for patients as well as their enrollment in future therapeutic trials.
Methods
CSF samples and case classification. We retrospectively analyzed CSF samples from 339 patients, 
including 282 samples sent for diagnostic purpose to the Laboratory of Neuropathology (NP-Lab), Institute 
of Neurological Sciences of Bologna (ISNB), 50 samples collected at the IRCCS Foundation Carlo Besta 
Neurological Institute (INCB), and 7 samples collected at the National CJD Research and Surveillance Unit of the 
UK. The study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guide-
lines and regulations. Informed consent was given by study participants or their next of kin. Data collection and 
CSF sample analysis of clinically suspected cases in Italy is an integral part of the National CJD surveillance study, 
which was approved by the Ethic Committee of the Istituto Superiore di Sanità (CE-ISS 09/266 on 29 may 2009).
CSF samples were collected by lumbar puncture (LP) following a standard procedure, centrifuged at 1000 × g 
for 10 min and stored in polypropylene tubes at −80 °C until analysis.
Molecular analysis of the PRNP gene was performed in all subjects as previously described37. All definitive 
cases were classified based on histopathological features, PRNP genotype and PrPSc type, as described9, 27, 38. The 
125 tested definite (sporadic or acquired) CJD included 43 MM(V)1 or MM(V)1+2 C (abbreviated in the man-
uscript as MM1), 33 VV2, 26 MV2K or MV2K+2 C (abbreviated as MV2K), and 23 cases of rarest subtypes (4 
Disease variants n Positive Negative Sensitivity (%)
definite sporadic CJD
MM1 43 40 3 93.0
VV2 33 33 0 100.0
MV2K 26 24 2 92.3
MM2C 9 6 3 66.7
MM2T§ 4 3 1 75.0
VV1 1 1 0 —
genetic CJD
E200K-129M 20 20 0 100.0
V210I-129M 10 10 0 100.0
D178N-129V 1 1 0 —
R208H-129V 1 1 0 —
E219G-129V 1 1 0 —
Other variants
GSS (P102L) 3 1 2 25.0
GSS (D202N) 1 0 1 —
GSS (A117V) 1 1 0 —
GSS (ins-8 repeats) 1 0 1 —
FFI 2 0 2 0
VPSPr 3 3 0 100.0
vCJD 4 1 3 25,0
iCJD 2 2 0 100.0
probable sporadic CJD
MM 39 38 1 97.4
MV 24 22 2 91.7
VV 10 9 1 90.0
Table 3. Sensitivity of IQ-CSF in sCJD, gCJD and other rare prion disease variants. §Include one probable case 
(see also methods).
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MM2T, 9 MM2C, 3VPSPr, 1VV1, 4 vCJD and 2 dura-mater associated iCJD MM1). The 73 probable sCJD cases 
were classified based on codon 129 genotype and included 39 MM, 24 MV and 10 VV subjects. A single case was 
classified as probable MM2T based on typical clinical, polysomnographic and PET findings39 and added to the 
MM2T group (n = 4) (Tables 1 and 3). The 41 genetic cases included the following PRNP haplotypes/mutations: 
E200K-129M (n = 20), V210I-129M (n = 10), D178N-129M, D178N-129V, R208H-129M, P102L-129M, E219G-
129V, D202N, A117V, ins-8 repeats (all n = 1). Finally, the non-CJD group included 100 cases with clinical fea-
tures compatible with CJD, in which post-mortem findings, including histopathological and PrP western blot 
analysis, or the results of laboratory investigation at follow-up excluded the diagnosis of prion disease (Table 2). 
Specifically, definitive clinical diagnosis included a) neurodegenerative diseases linked to a proven pathogenic 
mutation, b) autoimmune encephalitis with anti-(onco)neuronal antibodies (paraneoplastic encephalitis) or 
membrane-associated antineuronal antibodies (non-paraneoplastic autoimmune encephalitis) in serum and/or 
CSF, and infectious encephalitis confirmed by laboratory microbiological findings and c) metabolic/toxic enceph-
alopathies confirmed by clinical (follow-up), neuroradiological and laboratory findings.
PrPSc detection by RT-QuIC. CSF samples were analyzed by the RT-QuIC assay with two different protocols. 
The PQ-CSF protocol was previously described27. For IQ-CSF protocol, 15 µl of each CSF sample were added in 
the dark to 85 µl of reaction mix in black, clear-bottom, 96-well microplates. Samples were tested in quadruplicate 
together with positive (definite CJD) and negative (non-CJD) controls. The RT-QuIC reaction mix contained 10 
mM phosphate buffer at pH 7.4, 300 mM NaCl, 1 mM ethylenediaminetetraacetic acid tetrasodium salt dihydrate 
(EDTA) at pH 8.0, 10 μM thioflavin-T (ThT), 0.002% of Sodium dodecyl sulfate (SDS) and 0.1 mg/ml of Syrian 
hamster recombinant truncated form of prion protein (Ha rPrP 90–231)28. All the reaction solutions were freshly 
prepared and filtered before use with 0.22 µm sterile filters. After sealing, the plate was incubated in a FLUOstar 
OMEGA reader (BMG Labtech, Germany) at 55 °C, over a period of 60 hours with intermittent cycles of shaking (60 
s, 700 rpm, double-orbital) and rest (60 s). The fluorescence intensity of ThT-PrPSc aggregates, expressed as relative 
fluorescence units (RFU), was taken every 45 minutes using 450 ± 10 nm (excitation) and 480 ± 10 nm (emission) 
wave-lengths, with a bottom read and a gain of 1000. A CSF sample was considered prion positive if at least two out 
four sample replicates gave a fluorescence signal higher than the threshold cut-off value. This threshold represents 
the mean RFU values of negative samples plus at least 10 standard deviations. Samples were considered negative if 
none of the replicates surpassed the chosen cut-off. In two cases, only one of four replicate went over the threshold, 
thus the test was considered ambiguous/unclear and repeated.
14-3-3 protein detection and t-tau quantification in CSF. These assays were performed as described27. 
Briefly, protein 14-3-3 was evaluated semi-quantitatively by comparing the Western Blot signals of the tested sam-
ple in comparison to those of control samples (with a weak or a strong 14-3-3 signal, respectively). T-tau protein 
was quantitatively analyzed using commercially available kits based on a sandwich ELISA method, according to 
the manufacturer’s instructions (INNOTEST, Innogenetics, Gent, Belgium). Based on previous analyses27, the 
cut-off value chosen for t-tau was 1250 pg/ml.
Statistical analyses. RT-QuIC relative fluorescence responses were analysed and plotted using the Sigma 
Plot software (Systat Software Inc, Chicago, IL, USA). Depending on the data distribution, the Mann-Whitney 
test were used to test differences between two groups, while the one-way ANOVA (followed by Tukey’s or 
Bonferroni’s post hoc test) were applied for multiple group comparisons. P values < 0.05 is considered statisti-
cally significant. Unless otherwise stated, data are expressed as mean with standard error of the mean (SEM) and 
number of sample tested (n).
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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